APhA opposes HHS peptide policy
American Pharmacists Association (APhA) urges HHS to withdraw its interim peptide policy and keep the 503A Bulks List process during FDA’s review.
Being an exceptional compounding professional means you never stop learning
We advocate for compounding pharmacies and facilities on a range of state and federal issues affecting patient access to compounded medications. We represent pharmacists and technicians in both traditional 503A compounding pharmacies and 503B outsourcing facilities, as well as prescribers, patients, educators, and suppliers. We’re 5,000 members strong and growing.
American Pharmacists Association (APhA) urges HHS to withdraw its interim peptide policy and keep the 503A Bulks List process during FDA’s review.
Kentucky rejects HHS’s peptide policy, while Alabama boards issue peptide and GLP-1 guidance. Federal policy doesn’t guarantee uniform state rules.
APC and NCPA urge HHS to clarify its peptide enforcement discretion policy, add safeguards, and publish an FAQ for pharmacies and state regulators.
Read APC's joint comment letter with the National Community Pharmacists Association regarding HHS' interim peptide policy
States are responding differently to HHS’s peptide policy. Where Utah, Arizona, Massachusetts, and Illinois stand, and what 2027 bills could mean.
Unapproved obesity drug spawns a black market frenzy